LAURUS LABS
Laurus Labs Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in LAURUS LABS
Start SIPLaurus Labs Share Price
Laurus Labs Investment Rating
-
Master Rating:
-
Laurus Labs has an operating revenue of Rs. 5,568.42 Cr. on a trailing 12-month basis. An annual revenue growth of 2% is not great, Pre-tax margin of 22% is great, ROE of 24% is exceptional. The company has a reasonable debt to equity of 18%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 90 which is a GREAT score indicating consistency in earnings, a RS Rating of 7 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 124 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 |
|---|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 1,498 | 1,495 | 1,378 | 933 | 1,176 | 1,221 | 1,399 |
| Operating Expenses Qtr Cr | 1,072 | 1,077 | 1,005 | 717 | 842 | 858 | 936 |
| Operating Profit Qtr Cr | 426 | 418 | 373 | 215 | 334 | 363 | 462 |
| Depreciation Qtr Cr | 76 | 66 | 61 | 60 | 59 | 55 | 51 |
| Interest Qtr Cr | 38 | 28 | 29 | 21 | 21 | 25 | 21 |
| Tax Qtr Cr | 89 | 96 | 64 | 33 | 61 | 68 | 104 |
| Net Profit Qtr Cr | 227 | 232 | 221 | 109 | 198 | 222 | 293 |
Laurus Labs Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 0
- 20 Day
- 447.76
- 50 Day
- 474.39
- 100 Day
- 496.93
- 200 Day
- 513.39
- 20 Day
- 449.4
- 50 Day
- 479.55
- 100 Day
- 510.47
- 200 Day
- 530.26
Laurus Labs Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 422.7 |
| Second Resistance | 426.85 |
| Third Resistance | 431.7 |
| RSI | 35.72 |
| MFI | 25.96 |
| MACD Single Line | -14.06 |
| MACD | -16.3 |
| Support | |
|---|---|
| First Resistance | 413.7 |
| Second Resistance | 408.85 |
| Third Resistance | 404.7 |
Laurus Labs Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 2,251,503 | 87,470,892 | 38.85 |
| Week | 5,185,436 | 179,882,768 | 34.69 |
| 1 Month | 2,043,307 | 80,792,378 | 39.54 |
| 6 Month | 1,641,949 | 68,715,571 | 41.85 |
Laurus Labs Result Highlights
Laurus Labs Synopsis
NSE-Medical-Diversified
Laurus Labs is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 4707.04 Cr. and Equity Capital is Rs. 107.47 Cr. for the Year ended 31/03/2022. Laurus Labs Ltd. is a Public Limited Listed company incorporated on 19/09/2005 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24239AP2005PLC047518 and registration number is 047518.| Market Cap | 22,763 |
| Sales | 5,304 |
| Shares in Float | 39.23 |
| No of funds | 256 |
| Yield | 0.47 |
| Book Value | 6.72 |
| U/D Vol ratio | 0.7 |
| LTDebt / Equity | 16 |
| Alpha | -0.09 |
| Beta | 0.96 |
Laurus Labs
| Owner Name | Sep-22 | Jun-22 | Mar-22 | Dec-21 |
|---|---|---|---|---|
| Promoters | 27.27% | 27.27% | 27.27% | |
| Mutual Funds | 5.5% | 4.77% | 3.51% | |
| Insurance Companies | 3.48% | |||
| Foreign Portfolio Investors | 22.67% | 21.96% | 22.43% | |
| Financial Institutions/ Banks | ||||
| Individual Investors | 27.96% | 28.42% | 31.15% | |
| Others | 13.12% | 17.58% | 15.64% |
Laurus Labs Management
| Name | Designation |
|---|---|
| Dr. M Venu Gopala Rao | Non Exe.Chairman&Ind.Director |
| Dr. C V Lakshmana Rao | Executive Director |
| Dr. Satyanarayana Chava | Executive Director & CEO |
| Mr. V V Ravi Kumar | Executive Director & CFO |
| Mr. Chandrakanth Chereddi | Non Executive Director |
| Dr. Ravindranath Kancherla | Independent Director |
| Mrs. Aruna Rajendra Bhinge | Independent Director |
| Dr. Rajesh Koshy Chandy | Independent Director |
Laurus Labs Forecast
Price Estimates
Laurus Labs Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2022-10-21 | Quarterly Results & Interim Dividend | |
| 2022-07-27 | Quarterly Results | |
| 2022-04-28 | Audited Results & Interim Dividend | |
| 2022-01-27 | Quarterly Results | |
| 2021-10-28 | Quarterly Results & Interim Dividend |
| Date | Purpose | Remarks |
|---|---|---|
| 2022-11-04 | INTERIM | Rs.0.80 per share(40%)Interim Dividend |
| 2022-05-11 | INTERIM | Rs.1.20 per share (60%) Second Interim Dividend |
| 2021-11-18 | INTERIM | Rs.0.80 per share(40%)Interim Dividend |
| 2021-05-12 | INTERIM | Rs.0.80 per share (40%) Third Interim Dividend |
| 2021-02-09 | INTERIM | Re.0.40 per share (20%) Second Interim Dividend |
| Date | Purpose | Remarks |
|---|---|---|
| 2020-09-30 | Split | Rs.0.00 split from Rs. 10/- to Rs. 2/-. |
About Company
Laurus Labs FAQs
What is Share Price of Laurus Labs ?
Laurus Labs share price is ₹423 As on 04 December, 2022 | 18:10
What is the Market Cap of Laurus Labs ?
The Market Cap of Laurus Labs is ₹22762.5 Cr As on 04 December, 2022 | 18:10
What is the P/E ratio of Laurus Labs ?
The P/E ratio of Laurus Labs is 26.2 As on 04 December, 2022 | 18:10
What is the PB ratio of Laurus Labs ?
The PB ratio of Laurus Labs is 6.8 As on 04 December, 2022 | 18:10